Latest News

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Pathologists should try to educate oncologists about the sensitivity and specificity of assays to help optimize care plans, said David Rimm, MD, PhD.

Subcutaneous mosunetuzumab achieved consistent rates of complete responses across various high-risk marginal zone lymphoma subgroups.

Treatment-related AEs with sunvozertinib were consistent with EGFR tyrosine kinase inhibitors in patients with NSCLC with EGFR exon 20 insertion mutations.

Beyond DNA-centric diagnostics, protein-based methods may play a role in accurately matching patients with the most effective therapies.

Biomarker research is needed to better ascertain patient benefit with tarlatamab among those with relapsed extensive-stage small cell lung cancer.

Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.

There will be an unmet need for therapy in patients with aggressive lymphomas who did not benefit from therapy with bispecifics, CAR-T, chemotherapy, and targeted therapy.

Data from the phase 3 IMforte trial support the FDA approval of maintenance lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer.

A real-world, retrospective analysis showed that CRS and ICANS occurred in 48% and 16% of patients with ES-SCLC who were treated with tarlatamab.

The decision is based on phase 3 DESTINY-Breast11 trial data, in which the investigational regimen displayed improved pCR vs SOC in this breast cancer population.

Combination therapy of ETX-636 plus fulvestrant is being administered to patients with HR–positive, HER2-negative breast cancer in a phase 1/2 trial.

David Rimm, MD, PhD, discussed how AI tools may help automate routine tasks for pathologists and predict genomic alterations from images.

The recent accelerated approval of tarlatamab marks a significant milestone in treating relapsed extensive-stage small cell lung cancer (ES-SCLC).

Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.

The subcutaneous formulation of mosunetuzumab will require 17 cycles of therapy, without any maintenance, and can be done in outpatient settings.

D-VRd had a 72% chance of providing superior PFS outcomes vs isatuximab plus VRd in patients with transplant-ineligible NDMM.

Twice-daily thoracic radiotherapy appeared to confer less leukocyte and lymphocyte depletion compared with once-daily radiation in LS-SCLC.

Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.

A phase 1 trial is evaluating UB-VV111 with and without rapamycin as treatment for patients with CLL and LBCL who received at least 2 prior therapies.

In the phase 3 EMBER-3 trial, Guardant360 CDx was used to identify patients with ESR1-mutated advanced breast cancer who may benefit from imlunestrant.

Respiratory, viral, and bacterial infections have emerged as a toxicity of note during bispecific antibody treatment for indolent lymphoma.

David Rimm, MD, PhD, shared the rationale behind developing an AI-driven tool for quantifying tumor-infiltrating lymphocytes in melanoma.

Tarlatamab has demonstrated superiority to lurbinectedin as a treatment for patients with ES-SCLC who have progressed after frontline chemoimmunotherapy.

The RadComp Consortium trial showed comparable HRQOL between proton and photon therapy for patients with non-metastatic breast cancer.

Biomarker research may better elucidate clinical benefit and identify mechanisms of resistance with tarlatamab in extensive-stage small cell lung cancer.

SBRT achieved a 5-year DFS of 89% vs 92% with moderately hypofractionated IMRT in patients with intermediate risk prostate cancer.

The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.

Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.

Treatment with anito-cel shows a predictable and manageable safety profile among those with relapsed/refractory multiple myeloma in the iMMagine-1 trial.

The efficacy of TTFields was greater among patients who received immune checkpoint inhibition for the treatment of brain metastatic NSCLC.